Adrenal Insufficiency: Clinical Trials

23 trials for Adrenal Insufficiency, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

19 completed, 2 terminated, 2 unknown. 23 Phase 3, 8 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 323Completed 19, Terminated 2, Unknown 2
Phase 28Completed 7, Unknown 1

Follow Adrenal Insufficiency: new trials by email Literature Review of Adrenal Insufficiency trials Research Report on Adrenal Insufficiency

Trials (filtered) newest first · largest first

All 23 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Plasma Exchange With Albumin in AMN Patients
Albumin solution - Adrenomyeloneuropathy, Adrenoleukodystrophy
Phase 2 / Phase 3CompletedPujol, Aurora, M.D.52020-03-092022-09-22
Safety and Efficacy of Prednisolone in Adrenal Insufficiency Disease (PRED-AID Study)
Prednisolone, Hydrocortisone - Adrenal Insufficiency
Phase 3UnknownImperial College London442019-07-312023-09-01
Low Dose of Hydrocortisone and Fludrocortisone in Adult Cardiogenic Shock.
Hydrocortisone + Flucortac, Placebo - Cardiogenic Shock
Phase 3CompletedCMC Ambroise Paré3802019-04-192026-05-19
A Clinical Study to Assess the Efficacy and Safety of Gene Therapy for the Treatment of Cerebral Adrenoleukodystrophy (CALD)
Lenti-D - Cerebral Adrenoleukodystrophy (CALD)
Phase 3CompletedGenetix Biotherapeutics Inc.352019-01-242024-05-24
Is Adrenal Insufficiency Under-diagnosed in Hospitalized Cirrhosis Patients?
Cosyntropin - Adrenal Insufficiency, Cirrhosis
Phase 3CompletedUniversity of Virginia1002018-01-292021-12-09
A Clinical Study to Evaluate the Efficacy and Safety of MIN-102 (IMP) in Male AMN Patients
Leriglitazone, Placebo - Adrenoleukodystrophy
Phase 2 / Phase 3CompletedMinoryx Therapeutics, S.L.1162017-12-082026-10-28
Extension Study for Patients Entered Into Study Infacort 003
Infacort® - Adrenal Insufficiency
Phase 3CompletedNeurocrine UK Limited182016-03-042026-10-02
Treatment of Adrenal Insufficiency in Children
Infacort® - Adrenal Insufficiency
Phase 3CompletedNeurocrine UK Limited242015-03-012026-10-02
MD1003-AMN MD1003 in Adrenomyeloneuropathy
MD1003 100 mg capsule, Placebo - Adrenomyeloneuropathy, Adrenoleukodystrophy
Phase 2 / Phase 3CompletedMedDay Pharmaceuticals SA672014-10-012017-10-09
A Study of the Efficacy and Safety of Hematopoietic Stem Cells Transduced With Lenti-D Lentiviral Vector for the Treatment of Cerebral Adrenoleukodystrophy (CALD)
Lenti-D Drug Product (eli-cel) - Cerebral Adrenoleukodystrophy (CALD)
Phase 2 / Phase 3CompletedGenetix Biotherapeutics Inc.322013-08-212022-04-25
Effects of Steroid Replacement Therapy on Metabolic, Cardiovascular and Bone Outcomes in Adrenal Insufficiency
dual-release hydrocortisone, Conventional glucocortidois - Adrenal Insufficiency
Phase 3CompletedUniversity of Palermo882012-01-012024-02-15
Corticosteroid Therapy for Glucocorticoid Insufficiency Related to Traumatic Brain Injury
Placebo, Hydrocortisone Fludrocortisone - Traumatic Brain Injury, Trauma
Phase 3CompletedNantes University Hospital3362010-08-012017-09-14
Glucocorticoid Treatment in Addison's Disease
Solu-Cortef (hydrocortisone), Cortef (hydrocortisone) - Addison's Disease
Phase 2 / Phase 3CompletedHaukeland University Hospital332010-02-012013-03-20
Septic Shock em Steroids
Hydrocortisone - Mechanical Ventilation, Mortality
Phase 2 / Phase 3UnknownUnidade de Terapia Intensiva1602008-05-012010-01-13
ALD-101 Adjuvant Therapy of Unrelated Umbilical Cord Blood Transfusion (UCBT) in Patients With Inherited Metabolic Diseases
ALD-101 - Inherited Metabolic Diseases, Lysosomal Storage Disorders
Phase 3TerminatedAldagen402008-03-012014-07-08
Once-daily Oral Modified Release Hydrocortisone in Patients With Adrenal Insufficiency
hydrocortisone (modified release), oral tablet 20 and 5 mg, Hydrocortisone, oral tablet, 10 mg - Adrenal Insufficiency
Phase 2 / Phase 3CompletedShire642007-08-212020-11-24
Combination of Corticotherapy and Intensive Insulin Therapy for Septic Shock
recombinant human insulin, hydrocortisone, fludrocortisone - Septic Shock
Phase 3CompletedUniversity of Versailles5082006-01-012010-04-06
A Phase III Trial of Lorenzo's Oil in Adrenomyeloneuropathy
Lorenzo's oil - Adrenomyeloneuropathy, Adrenoleukodystrophy
Phase 3TerminatedEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)2402005-03-012012-03-02
Dehydroepiandrosterone Substitution in Adolescent and Young Women With Central Adrenal Insufficiency
Dehydroepiandrosterone, placebo - Adrenal Insufficiency
Phase 3CompletedUniversity Hospital Tuebingen232003-10-012007-12-18
Corticosteroid Therapy of Septic Shock - Corticus
hydrocortisone sodium succinate, Placebo - Shock, Septic
Phase 3CompletedHadassah Medical Organization5002002-03-012008-04-24

Showing 20 of 23. Sign in to see all of them.

Narrower conditions

Adrenoleukodystrophy (9)  ·  Addison Disease (3)  ·  Fucosidosis (2)  ·  Gangliosidosis, GM1 (2)  ·  Leukodystrophy, Globoid Cell (2)  ·  Leukodystrophy, Metachromatic (2)  ·  Sandhoff Disease (2)  ·  Shock (2)  ·  Shock, Septic (2)  ·  Tay-Sachs Disease (2)  ·  Abetalipoproteinemia (1)  ·  Brain Injuries, Traumatic (1)  ·  Canavan Disease (1)  ·  Cholestasis (1)

Broader conditions

Adrenal Gland Diseases (23)  ·  Endocrine System Diseases (22)  ·  Brain Diseases (10)  ·  Central Nervous System Diseases (10)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (10)  ·  Genetic Diseases, Inborn (10)  ·  Metabolic Diseases (10)  ·  Nervous System Diseases (10)  ·  Nutritional and Metabolic Diseases (10)  ·  Brain Diseases, Metabolic (9)  ·  Brain Diseases, Metabolic, Inborn (9)  ·  Demyelinating Diseases (9)  ·  Genetic Diseases, X-Linked (9)  ·  Hereditary Central Nervous System Demyelinating Diseases (9)

Interventions

Hydrocortisone (8)  ·  Dehydroepiandrosterone (2)  ·  Antilymphocyte Serum (1)  ·  Biotin (1)  ·  Bone Marrow Transplantation (1)  ·  Busulfan (1)  ·  Cholic Acid (1)  ·  Cholic Acids (1)  ·  Cortisone (1)  ·  Cosyntropin (1)  ·  Cyclophosphamide (1)  ·  Fludrocortisone (1)  ·  Lorenzo's oil (1)  ·  Plasma Exchange (1)  ·  Prednisolone (1)

Sponsors

Genetix Biotherapeutics Inc. (2)  ·  Neurocrine UK Limited (2)  ·  Aldagen (1)  ·  CMC Ambroise Paré (1)  ·  Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (1)  ·  Hadassah Medical Organization (1)  ·  Haukeland University Hospital (1)  ·  Imperial College London (1)  ·  Masonic Cancer Center, University of Minnesota (1)  ·  MedDay Pharmaceuticals SA (1)  ·  Minoryx Therapeutics, S.L. (1)  ·  Mirum Pharmaceuticals, Inc. (1)  ·  Nantes University Hospital (1)  ·  National Center for Research Resources (NCRR) (1)  ·  Pujol, Aurora, M.D. (1)

Countries

France (8)  ·  Germany (8)  ·  United States (8)  ·  United Kingdom (5)  ·  Italy (3)  ·  Netherlands (3)  ·  Spain (3)  ·  Argentina (1)  ·  Australia (1)  ·  Austria (1)  ·  Belgium (1)  ·  Brazil (1)  ·  Hungary (1)  ·  Israel (1)  ·  Norway (1)

Top investigators

Paul Orchard, MD (2)  ·  Adrian Thrasher, MD, PhD (1)  ·  Anna G Nilsson, MD, PhD (1)  ·  Charles L Sprung, MD (1)  ·  Christine Duncan, MD (1)  ·  David Williams, MD (1)  ·  Didier Keh, MD (1)  ·  Didier Pittet, MD (1)  ·  Djillali Annane, MD (1)  ·  Florian Eichler, MD (1)  ·  Frederic Sedel, MD (1)  ·  Gerald V Raymond, M.D. (1)  ·  Gerhard Binder, PD Dr. med. (1)

Results publications

PMID 39383458, PMID 18184957, PMID 20103758, PMID 21586746, PMID 22073145, PMID 25066331, PMID 28644367, PMID 28976817, PMID 33236103, PMID 34980224, PMID 36681445, PMID 39171906, PMID 39383459, PMID 41874506

NIH funding

2018 (2), 2009 (1)